Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(67%)

Phase Distribution

Ph not_applicable
3
100%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
N/ANon-phased studies
3(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(2)

Detailed Status

Terminated2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
33.3%
Most Advanced
N/A

Trials by Phase

N/A3 (100.0%)

Trials by Status

terminated267%
completed133%

Recent Activity

0 active trials
Showing 3 of 3
completednot_applicable

Study of a Cilioscleral Interposition Device (CID) SV22 in Patients With Primary Open Angle Glaucoma and Narrow Angle Glaucoma

NCT05236439
terminatednot_applicable

Study of a Novel Interposition Supraciliary Implant in Patients With Open Angle Glaucoma (SAFARI 2)

NCT04770324
terminatednot_applicable

Study of a Novel Interposition Supraciliary Implant in Patients With Open Angle Glaucoma

NCT03736655

Clinical Trials (3)

Showing 3 of 3 trials
NCT05236439Not Applicable

Study of a Cilioscleral Interposition Device (CID) SV22 in Patients With Primary Open Angle Glaucoma and Narrow Angle Glaucoma

Completed
NCT04770324Not Applicable

Study of a Novel Interposition Supraciliary Implant in Patients With Open Angle Glaucoma (SAFARI 2)

Terminated
NCT03736655Not Applicable

Study of a Novel Interposition Supraciliary Implant in Patients With Open Angle Glaucoma

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
3